Physician profile
Prethy Rao
NPI 1982967998
$85,112.47
in general payments reported to CMS, 2019-2025
23 companies · $35K in 2025
The $35K reported for 2025 was more than what 98% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $149 · 2020: $158 · 2021: $981 · 2022: $5,012 · 2023: $19K · 2024: $25K · 2025: $35K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $54K · Travel and Lodging: $15K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,609 · Food and Beverage: $4,339.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $53,810.00 |
| Travel and Lodging | $15,054.98 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,608.67 |
| Food and Beverage | $4,339.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $49,325.22 | 2022-2025 | Stellaris, Stellaris Elite, Surgical Misc |
| Regeneron Healthcare Solutions, INC. | $17,364.91 | 2021-2025 | Eylea Hd, Eylea |
| Genentech USA, INC. | $6,144.02 | 2021-2025 | Vabysmo |
| Genentech, INC. | $4,696.00 | 2021-2023 | Vabysmo |
| Dutch Ophthalmic, USA | $2,954.79 | 2022 | |
| Eyepoint US, INC. | $2,862.53 | 2021-2024 | |
| Regeneron Pharmaceuticals, INC. | $353.49 | 2021-2022 | |
| Alcon Vision LLC | $240.52 | 2020-2023 | Constellation |
| Apellis Pharmaceuticals, INC. | $229.69 | 2023-2025 | Syfovre |
| Allergan, INC. | $148.84 | 2019 | |
| Abbvie INC. | $131.48 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $130.33 | 2021 | |
| Samsara Vision | $119.58 | 2025 | Implantable Miniature Telescope (Imt By Dr. Isaac Lipshitz) |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $118.44 | 2021 | |
| Oculus Surgical INC. | $86.82 | 2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $53.63 | 2023-2024 | Byooviz |
| Astellas US LLC | $44.03 | 2024 | Izervay |
| Springworks Therapeutics, INC. | $27.24 | 2025 | Gomekli |
| Boston Scientific Corporation | $24.27 | 2021 | |
| Harrow Eye, LLC | $19.98 | 2023 | Iheezo |
| Alimera Sciences, INC. | $18.87 | 2023 | Iluvien |
| Eyevance Pharmaceuticals LLC | $17.79 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prethy Rao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.